Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Genfit's French Fans Fume Following Failure of Fatty Liver Drug

thestreet.com — BOSTON ( TheStreet) -- French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505. I know this because many of them (it feels like all of them!)

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

thestreet.com — Don't tell the "biotech bubble" people about all of these cash deals. Shhh! - Brad Loncar (@bradloncar) March 30, 2015 I disagree with Brad Loncar's suggestion that the biotech bubble debate is put to bed by Monday's M&A activity -- Teva buying Auspex Pharmaceuticals for $3.5 billion and Horizon Pharma acquiring Hyperion Therapeutics for $1.1 billion.

Teva Buying Auspex Pharma for $3.5 Billion in Bid to Restart Growth

thestreet.com — JERUSALEM ( TheStreet) -- Teva is acquiring Auspex Pharmaceuticals for $3.5 billion to expand its core business treating patients with diseases of the central nervous system. The deal values Auspex at $101 per share, a 42% premium to the Friday close of $70.91.

Horizon Pharma Buying Orphan Drug Maker Hyperion for $1.1 Billion

thestreet.com — DUBLIN, Ireland ( TheStreet) -- Horizon Pharma is buying Hyperion Therapeutics for $1.1 billion to expand its portfolio of drugs treating rare diseases, the companies announced Monday. The all-cash deal values Hyperion at $46 a share, an 8% premium to Friday's close of $42.74.

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study

thestreet.com — LILLE, France ( TheStreet) -- Torture a prisoner long enough and he'll tell you what you want to hear. Clinical trials are similarly vulnerable. Just ask Genfit , which put its fatty liver drug candidate GFT505 through the statistical equivalent of waterboarding and sleep deprivation to extract the desired result from a mid-stage study: The drug works!

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

thestreet.com — NEW YORK ( TheStreet) -- Biotech stocks started the year red hot, but as spring approaches, the sector is rolling over. Selling begets more selling. Concerns about drug pricing and absurd valuations dominate the conversation. Columnists write stories about a bursting biotech bubble. A gloom settles over the biotech sector.

Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy

thestreet.com — NEW YORK (TheStreet) -- The next investor referendum on the resurgent gene-therapy field will arrive next month when Celladon Therapeutics is expected to announce results from a mid-stage study of a gene therapy aimed at improving the heart's pumping ability in patients suffering from the organ's advanced failure.

PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company

thestreet.com — NEW YORK ( TheStreet) -- Biotech CEOs are supposed to be cheerleaders, so it's noteworthy when a CEO's pocketbook indicates otherwise. Case in point: PTC Therapeutics CEO Stu Peltz no longer owns his company's stock. Peltz sold his remaining 47,200 shares in the orphan disease drugmaker on Monday, according to an SEC filing.

High Alert for Signs of Biotech Collapse Makes for Nervous Investors

thestreet.com — NEW YORK ( TheStreet) -- Baird analyst Brian Skorney spent the weekend talking on the phone and trading emails with his institutional investor clients, allaying fears that the biotech sector was going to be decimated on Monday morning.

Vertex Cystic Fibrosis Drug Smacked by Burden of High Expectations

thestreet.com — BOSTON ( TheStreet) -- Vertex Pharmaceuticals is developing a new cystic fibrosis drug VX-661 designed to be more effective than an existing drug lumacaftor and work better in future combination therapies for the most difficult-to-treat cystic fibrosis patients. On Monday, Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped.
More Articles →
Mar 31, 2015

@cbloggy Incredible and so frightening. I just told my sis-in-law visiting us from Berkeley. She wants to cry.

Mar 31, 2015

wow RT @cbloggy: Bad #CADrought news tomorrow: snowpack in Sierras, usually 66.5 inches on April 1, will be zero. That's our drinking water.

Mar 31, 2015

RT @ThisIsFusion: This totally wins the internet today: Seven Nation Army by The White Stripes w/ Maple

Mar 31, 2015

@zbiotech C’mon, it’s a small, short ph1b study. Nothing could possibly go wrong from here.

Mar 31, 2015

@shaneblackmon Yet $CRMD is a top-performing stock this quarter. Crazy times…

Mar 31, 2015

A good read on today’s $CLDN “mITT” CUPID-2 controversy —> RT @Ogut_Ozgur: ITT Treasure Hunt $CLDN bit.ly/1bOlkmk

Mar 31, 2015

RT @AndyBiotech: LOL this time for real -> RT @biotechvalue: $CLDN shelf, not to be confused with the Celadon shelf ir.celladon.com/secfiling.cfm?…

Email Adam by joining Muck Rack Pro



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile